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Abstract
Cancer-associated fibroblasts (CAFs) are key regulators of tumorigen-
esis and promising targets for next-generation therapies. We discov-
ered that cancer cell-derived activin A reprograms fibroblasts into
pro-tumorigenic CAFs. Mechanistically, this occurs via Smad2-
mediated transcriptional regulation of the formin mDia2, which
directly promotes filopodia formation and cell migration. mDia2 also
induces expression of CAF marker genes through prevention of p53
nuclear accumulation, resulting in the production of a pro-tumori-
genic matrisome and secretome. The translational relevance of this
finding is reflected by activin A overexpression in tumor cells and of
mDia2 in the stroma of skin cancer and other malignancies and the
correlation of high activin A/mDia2 levels with poor patient survival.
Blockade of this signaling axis using inhibitors of activin, activin
receptors, or mDia2 suppressed cancer cell malignancy and squa-
mous carcinogenesis in 3D organotypic cultures, ex vivo, and in vivo,
providing a rationale for pharmacological inhibition of activin
A-mDia2 signaling in stratified cancer patients.
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Introduction
Skin cancer is by far the most common type of cancer worldwide,
and non-melanoma skin cancers (NMSC) are particularly common
(Lomas et al, 2012). About 5.4 million cases of NMSCs, which
include basal cell carcinoma (BCC), cutaneous squamous cell
carcinoma (cSCC), and a few less common malignancies, were
treated in the United States in 2012, and their incidence is increasing
at an alarming rate (Rogers et al, 2015). This is mainly a conse-
quence of the increased life expectancy, the extended sun exposure,
and the use of immunosuppressive therapy in organ transplant
patients (Lanz et al, 2019). Therefore, there is a strong need to
unravel the molecular drivers of these tumors and to develop new
strategies for efficient prevention and treatment of NMSCs.
In addition to mutations and epigenetic changes in the tumor
cells, alterations in stromal cells strongly contribute to carcinogene-
sis (Dotto, 2014; Curtius et al, 2018). Therefore, treatments target-
ing different components of the tumor microenvironment (TME),
such as the tumor’s blood and lymphatic vasculature as well as
cancer-associated immune cells, have been proposed (Binnewies
et al, 2018). A particularly important component of the TME are
CAFs (Kalluri, 2016). They reside at the tumor margin or infiltrate
the tumor, and affect cancer development by secreting various
growth factors, cytokines, chemokines, proteinases, and extracellu-
lar matrix (ECM) proteins (Madar et al, 2013). These features of
CAFs are relatively well characterized and in most cases pro-tumori-
genic (Gascard & Tlsty, 2016). However, the factors responsible for
the induction of a CAF phenotype in different cancers and their
molecular targets are still understudied.
Here, we identified activin A as a major player in CAF differentia-
tion. This transforming growth factor b (TGF-b) family member is
mainly known as a reproductive hormone, but potent activities of
activin A in tissue repair and fibrosis have also been discovered
(Werner & Alzheimer, 2006; Hedger & de Kretser, 2013). Consistent
with the remarkable parallels between tissue repair and cancer
(Schafer & Werner, 2008), important roles of activin A in different
malignancies are emerging (Antsiferova & Werner, 2012), although
the underlying mechanisms are still largely unexplored. Interestingly,
expression of activin A is strongly upregulated in human BCCs and
cSCCs (Antsiferova et al, 2011). This is functionally relevant, since we
previously showed that overexpression of activin A in keratinocytes
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of transgenic mice to a similar extent as in human SCCs promoted
formation of skin papillomas and their malignant progression in a
non-cell-autonomous manner (Antsiferova et al, 2011). However,
genetic or pharmacological depletion of different immune cells did not
or only partially suppress the activin A-induced promotion of squa-
mous carcinogenesis (Antsiferova et al, 2013, 2017), indicating key
roles of other cells of the TME in the development and progression of
NMSC. Most importantly, the molecular targets of activin A that drive
tumor development and progression are as yet unknown.
Here, we show that activin A induces a pro-tumorigenic CAF
phenotype in skin fibroblasts through activation of a Smad2-mDia2-
p53 signaling axis. This unexpected link between major regulators
of fibroblast function and tumorigenesis offers promising therapeu-
tic opportunities for the treatment of different malignancies.
Results
Activin A promotes SCC cell malignancy in a
non-cell-autonomous manner
To determine the potential involvement of non-immune cells in the
pro-tumorigenic activity of activin A, we used a xenograft model of
immunodeficient NOD/SCID mice. Weakly tumorigenic cSCC cells
(SCC13), which express low levels of endogenous activin A, were
transduced with lentiviruses expressing the inhibin/activin bA subunit
(INHBA) in a doxycycline (DOX)-inducible manner (SCC13 Act)
(Fig 1A). This mimics the situation in human NMSC, where INHBA is
up to 50-fold overexpressed in total tumor samples compared to
normal skin and even more in the cancer cells themselves (Antsiferova
et al, 2011). In DOX-treated SCC13 Act cells, INHBAmRNA levels were
approximately 70- to 90-fold increased, and activin bA precursor and
mature protein were detected in the lysate or medium, respectively
(Fig 1B). Expression of INHBB or INHA was not induced, suggesting
that overexpression of INHBA results mainly in production of activin
A. Expression of TGFB1 and of the secreted activin antagonist follis-
tatin (FST) was also not affected (Fig EV1A).
Activin A overexpression did not affect proliferation, migration,
or the epithelial phenotype of SCC13 cells in spite of efficient
nuclear translocation of SMAD2/3 (Fig EV1B and C). However,
upon intradermal injection of SCC13 cells or of highly malignant
A431 epidermoid vulvar carcinoma cells into ears of NOD/SCID
mice, the tumors formed by activin A-overexpressing cells were
larger compared to those formed by empty vector (EV)-transduced
cells (SCC13 EV, A431 EV) (Figs 1C–E and EV1D–H) and showed
invasive growth as revealed by penetration through the ear cartilage
(Fig 1D, inset). The cancer cells still expressed E-cadherin, but also
showed cytoplasmic/nuclear b-catenin (Fig EV1I). Areas with high
collagen density were significantly enlarged in these tumors, indicat-
ing a pro-fibrotic fibroblast phenotype (Fig 1F). Consistent with this
finding, the proliferation rate of stromal fibroblasts was significantly
increased (Fig 1G). There was no change or even a slight decrease
in the area covered by blood or lymphatic vessels (Fig EV1J and K),
which is consistent with the anti-angiogenic/anti-lymphangiogenic
role of activin A (Krneta et al, 2006; Kaneda et al, 2011; Heinz et al,
2015). Overall, these findings point to a role of fibroblasts in the
pro-tumorigenic effect of activin A.
Activin A promotes SCC cell malignancy in organotypic cultures
To further test this possibility, we established 3D organotypic cultures
of cancer cells with primary human dermal fibroblasts. Remarkably,
the epithelium formed by SCC13 Act cells was hyperthickened and
disorganized (Fig 1H and I), and the tumor cells invaded through the
basement membrane into the dermal equivalent (Fig 1J). This was
also observed with A431 cells and with SCC13 Act cells in co-culture
▸
Figure 1. Activin A promotes squamous cell malignancy and tumor growth in a xenograft model and in organotypic culture.
A qRT–PCR for INHBA relative to RPL27 using RNA from SCC13 cells transduced with a lentiviral vector allowing expression of INHBA in a doxycycline (DOX)-inducible
manner (SCC13 Act clone 1 and 2) or empty vector (EV) (N = 3). SCC13 Act and EV cell lines were generated from lentivirally transduced cells upon single-cell clonal
expansion.
B Western blot of cell lysate and conditioned media (CM; bottom) of transduced SCC13 cells for the activin bA subunit and GAPDH (loading control for cell lysate) under
reducing conditions. The higher molecular weight of recombinant activin bA results from the HA-epitope tag. Ponceau S staining of the membrane was used as a
loading control for the CM.
C Representative pictures of 5-week-old tumors (indicated by arrows) formed in NOD/SCID mice upon intradermal injection of SCC13 Act (clone 2) or SCC13 EV cells and
tumor volume at different time points of tumor development. N = 3–6 tumors.
D Representative images of H&E stainings of tumors formed by SCC13 EV and Act cells (clone 2) at day 35 (asterisk indicates cartilage; arrow indicates site of invasion).
An inset panel indicates the area where tumor cells invade into the cartilage. Tumor sections were evaluated for invasion through the basement membrane. N = 6
(EV), N = 6 Act (3 tumors from clone 1 and 3 tumors from clone 2). Tumors from Act mice were pooled in the graph.
E Tumor weight at endpoint (5 weeks after injection). N = 3–6 tumors.
F Herovici staining and quantification of percentage of collagen-positive (dark blue) area per field of view. N = 3 tumors, n = 3–4 histological sections.
G Representative images of sections from tumors formed by SCC13 EV and SCC13 Act cells (clone 2) stained for Ki67 (red), PDGFR-a (green), and counterstained with
Hoechst (blue). Quantification of Ki67/PDGFR-a-positive cells is shown in the graph. N = 3 tumors, n = 3–4 histological sections.
H Representative images of sections from 3D cultures of primary human skin fibroblasts with either SCC13 EV or SCC13 Act (clones 1 and 2) cells stained with either
H&E or Herovici.
I Quantification of Ki67-positive cells in sections from SCC13 EV and SCC13 Act (clone 2) organotypic cultures (co-stained with E-cadherin to indicate epithelial cells).
N = 3 independent cultures, n = 3 histological sections.
J Representative images of sections from SCC13 EV and SCC13 Act (clone 2) organotypic cultures stained for K14 (red) and collagen IV (green) combined with Hoechst
staining (blue) and quantification of the K14-positive area below the basement membrane (BM). N = 3 independent cultures, n = 4 histological sections. The area
indicated with a white rectangle in the left picture is shown at higher magnification in the right picture.
Data information: Bar graphs show mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (one-way ANOVA with Bonferroni post-test (A, J), two-way ANOVA
with Bonferroni post hoc test (C, I), unpaired Student’s t-test (E (combined), F, G), Fisher’s exact test (D)). Scale bars, 500 lm (D) or 100 lm (F–H, J). Exact P-values are
provided in Dataset EV3.
Source data are available online for this figure.
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with either primary or immortalized mouse fibroblasts (Fig EV2A and
B). Activin A-overexpressing cells showed various malignant features,
including reduced membrane staining for E-cadherin in cells at the
invasive front, cytoplasmic/nuclear b-catenin, and increased secretion
of active matrix metalloproteinases (MMP)-2 and MMP-9 (Fig EV2C–
E). Since these data show that activin A promotes invasive growth of
SCC cells via fibroblasts, we next determined whether activin A
directly affects these cells.
Activin A induces a CAF phenotype in skin fibroblasts
Recombinant activin A promoted proliferation of primary dermal
fibroblasts in a dose-dependent manner (Fig 2A). However, it did
not stimulate contraction of collagen gels by primary mouse and
human fibroblasts, while TGF-b1—a key regulator of myofibroblast
differentiation (Tomasek et al, 2002)—had a strong effect (Fig 2B;
Appendix Fig S1A). Activin A even inhibited this activity of TGF-b1
(Fig 2B). Although both activin A and TGF-b1 increased the expres-
sion of alpha smooth muscle actin (aSMA, encoded by the Acta2
gene), a marker for contractile myofibroblasts (Tomasek et al,
2002) (Fig 2C; Appendix Fig S1B), only the latter showed incorpora-
tion into stress fibers (Fig 2D), a characteristic feature of myofibro-
blasts (Clement et al, 2005). On the contrary, only activin A
enhanced the density and length of actin-rich filopodia and
promoted migration in scratch and chemotactic transwell assays
(Fig 2E–G). Since high motility is a hallmark of CAFs, including
cultured CAFs from human cSSCs (Commandeur et al, 2011), and
implicated in cancer cell invasion (Karagiannis et al, 2012; Kalluri,
2016), we determined whether activin A also induces the expression
of CAF marker genes in normal fibroblasts. Indeed, several skin
CAF marker genes, which encode predominantly cytokines and
ECM proteins (Procopio et al, 2015), were upregulated in activin A-
treated fibroblasts. Expression of endogenous Inhba was also
increased, indicating autoinduction (Fig 2H).
Activin A stimulates expression and release of tumor-promoting
factors in fibroblasts
To investigate the effect of activin A on the secretome and matri-
some of fibroblasts and the relevance of these secreted factors for
cancer cell behavior, we generated human primary fibroblasts with
DOX-inducible overexpression of activin A (Fb Act), thus mimicking
the activin A autoinduction seen upon exposure of fibroblasts to
exogenous activin A. We selected clones, which show a fourfold to
fivefold INHBA overexpression that is comparable to the overexpres-
sion seen in response to activin A treatment (Fig 3A and B). These
cells produced a secretome, which promoted migration and clono-
genicity of cancer cells and deposited increased levels of fibronectin
and collagen I (Fig 3C–E). To determine whether the deposited
matrix has pro-tumorigenic activities, we plated SCC13 cells on the
de-cellularized matrix deposited by either Fb Act or Fb EV cells.
Indeed, the colony-forming and migratory capacities of the cancer
cells were significantly higher on matrix deposited by activin-over-
expressing cells. A similar effect was seen in direct 2D co-culture
(Fig 3F–H). However, it was less pronounced, since ECM and condi-
tioned medium were collected for 3 days and the conditioned
medium was concentrated. The conditioned medium of Fb Act also
promoted anchorage-independent growth of SCC13 cells as shown
in a spheroid formation assay. However, recombinant activin A
alone had no effect in this assay (Fig 3I), suggesting that other
factors secreted by these cells, but not activin A itself, enhance
proliferation and invasive growth of cancer cells. Consistently,
expansion of SCC13 cells in 3D cultures was significantly increased
when the cancer cells were seeded on a dermal equivalent formed
by activin A-overexpressing fibroblasts (Fig 3J).
Most importantly, when SCC13 cells were co-injected with Fb
Act or EV, tumor formation was strongly accelerated upon DOX-
induced INHBA expression (Fig 3K). These data demonstrate that
activin A induces the production of secretomes and matrisomes by
fibroblasts, which promote tumor cell proliferation and invasive
growth.
Activin A induces CAF gene expression by fibroblasts in vivo
To unravel the molecular mechanisms underlying this effect, we
used a transgenic mouse model where skin papillomas form sponta-
neously due to expression of human papilloma virus 8 (HPV8) onco-
genes in keratinocytes (Schaper et al, 2005). When these mice
(HPV8/wt mice) were mated with transgenic mice overexpressing
INHBA in keratinocytes (wt/Act mice), HPV8-induced tumor
▸
Figure 2. Activin A induces a CAF phenotype in fibroblasts.
A Primary murine dermal fibroblasts, which had been treated with recombinant activin A at different concentrations, were analyzed for BrdU incorporation. N = 3–4.
B Representative images of collagen gels and quantification of the extent of gel contraction (percentage of initial gel size) in the presence or absence of activin A
(20 ng/ml) and/or TGF-b1 (1 ng/ml). N = 3–4.
C qRT–PCR and Western blot analyses of ACTA2/aSMA expression using total RNA/lysates of fibroblasts treated with activin A or TGF-b1 for 6 h. N = 3. The membrane
was re-probed with GAPDH and mDia2 antibodies.
D Representative images of fibroblasts treated with activin A, TGF-b1, or vehicle (control) as in (C), stained for aSMA (green), counterstained with rhodamine-coupled
phalloidin (red), and Hoechst (blue). Bar graph shows percentage of fibroblasts with stress fibers. N = 3.
E Representative images of control and activin A-treated fibroblasts stained with rhodamine-coupled phalloidin; scatter plot shows quantification of filopodium length
in control, activin A-treated, and TGF-b1-treated fibroblasts. N = 27–70 filopodia.
F Scratch assay of fibroblasts treated with activin A or vehicle for 24 h. N = 3. The area covered by cells in the original scratch was quantified. Migration in one control
culture was set to 1.
G Chemotactic migration of primary mouse fibroblasts from wt mice for 24 h in a transwell assay toward increasing concentrations of activin A or vehicle. N = 3.
H qRT–PCR analysis of CAF marker genes relative to Rps29 using RNA from fibroblasts treated with activin A for 6 h. N = 3.
Data information: Bar graphs show mean  SEM. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001 ****P < 0.0001 (one-way ANOVA with Bonferroni post-test (A-G) or
two-way ANOVA with Bonferroni post hoc test (H)). Scale bars: 50 lm (D) and 25 lm (E). Exact P-values are provided in Dataset EV3.
Source data are available online for this figure.
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formation was strongly accelerated (Antsiferova et al, 2017). We
then FACS-isolated fibroblasts from the ear skin of wild-type (wt/wt),
wt/Act, HPV8/wt, and HPV8/Act mice prior to the formation of
tumors and analyzed their expression profile by RNA sequencing.
The purity of this cell fraction was above 90% as determined by re-
analysis of the sorted cells (Fig EV3A and B). The number of cells
expressing the pan-fibroblast marker PDGFRa (CD140a) (Driskell
et al, 2013) and concomitantly lacking the immune cell marker
CD45 was significantly increased in mice expressing the INHBA
transgene, and there was a virtual absence of markers for keratino-
cytes and endothelial and immune cells in the sorted cells (Fig EV3C
and D). Expression of the HPV8 transgene in keratinocytes had no
major effect on the fibroblast transcriptome, while activin A overex-
pression in keratinocytes induced major changes in fibroblasts inde-
pendent of the HPV8 transgene (Fig EV3E). Gene set enrichment
analysis (GSEA) revealed that genes regulated by activin A in fibrob-
lasts showed a significant positive correlation with genes upregu-
lated in human skin SCCs, CAFs from SCCs of patients with
recessive dystrophic epidermolysis bullosa (RDEB) (Ng et al, 2012),
human actinic keratosis (AK), the major SCC precursor lesion
(Nindl et al, 2006), human breast cancer stroma (Planche et al,
2011; Harvell et al, 2013) and CAFs (Bauer et al, 2010), liver cancer
stroma (Sulpice et al, 2013), lung cancer stroma and CAFs (Navab
et al, 2011), and prostate cancer CAFs (Doldi et al, 2015), but nega-
tive correlation with the genes downregulated in CAFs versus
normal tissue fibroblasts (Fig 4A). Interestingly, the gene expression
signature of CAFs from Act mice was more similar to the signature
of cultured CAFs from the highly aggressive SCCs of RDEB patients
than to the signature of regular cSCC CAFs (Fig 4A; Ng et al, 2012).
Ingenuity pathway analysis (IPA) showed activin A-induced enrich-
ment of genes associated with “proliferation of tumor cells”, “migra-
tion of cells”, and “organization of cytoskeleton” (Fig 4B).
Importantly, activin A promoted the expression of various genes
encoding ECM components, ECM regulators, and secreted factors
(Fig 4C), providing a likely explanation for the pro-tumorigenic
activity of the matrisome and secretome of Fb Act cells.
Activin A transcriptionally activates mDia2 via Smad2
in fibroblasts
A class of genes that was strongly activated by activin A encodes
proteins involved in cell migration, including mDia2 (Diap3)
(Figs 4D and EV3E), a member of the formin family of cytoskeletal
regulators and key player in filopodium formation (Pellegrin &
Mellor, 2005; Beli et al, 2008). This is a direct effect, since recombi-
nant activin A induced mDia2/DIAPH3 expression in primary
murine and human fibroblasts (Figs 4E and EV3F). Importantly,
TGF-b1 treatment did not increase mDia2/DIAPH3 expression in
skin fibroblasts (Figs 4E and EV3F) or ovarian fibroblasts (Yeung
et al, 2013). Neither mDia1 nor mDia3 expression was induced in
Act mice or in activin A-treated cultured fibroblasts (Fig EV3G and
H). We identified a conserved “SMAD binding element” (SBE) in
the first intron of the mDia2 gene downstream of the transcription
start site (TSS), and activin A, but not TGF-b1, promoted binding of
SMAD2/3 to this SBE (Fig 4F). Consistent with the different activity
of activin A versus TGF-b1, activin A preferentially activated
SMAD2 rather than SMAD3 in other cells (Schmierer et al, 2003),
and Gene Transcription Regulation Database (GTRD) analysis
(Yevshin et al, 2017) predicted a higher number of SMAD2 binding
sites in the regulatory region of the mDia2 compared to the mDia1
and mDia3 genes (Fig EV3I). The role of activin receptor signaling
in the regulation of mDia2 expression was confirmed by expression
of a dominant-negative mutant of activin receptor IB (dnActRIB) in
fibroblasts, which reduced basal and activin A-induced mDia2
mRNA levels (Fig 4G).
mDia2 expression correlates with activin A levels in mouse xeno-
graft cancer samples as demonstrated by immunostaining of
sections from ear tumors. mDia2 was mainly expressed in the tumor
stroma, in particular in cells adjacent to the activin A-secreting
tumor cells, which are most likely fibroblasts (Fig 4H), suggesting
involvement of mDia2 in the pro-tumorigenic effect of activin A.
Furthermore, mDia2 co-localized with the vascular endothelial cell
marker cell MECA32, but not with the lymphatic endothelial cell
◀
Figure 3. Activin A-exposed fibroblasts produce a tumor-promoting secretome and matrisome.
A qRT–PCR for INHBA relative to RPL27 using RNA from primary human fibroblasts transduced with a lentiviral vector allowing expression of INHBA in an inducible
manner after treatment with DOX for 24 h (Fb Act, clones 1 and 2) or with empty vector (Fb EV) (N = 3). Fb Act and Fb EV cultures were generated from lentivirally
transduced cells upon clonal expansion of resistant single cells.
B Western blot of conditioned media (CM) of transduced fibroblasts showing mature activin bA. Ponceau S staining of the membrane was used as a loading control.
C Chemotactic migration of SCC13 cells for 24 h in a transwell assay containing CM from Fb Act (clone 2) or Fb EV. N = 4. Migration in one control culture was set to 1.
D Relative colony area of SCC13 cells upon culture in CM from Fb Act (clone 2) or EV. N = 3.
E Representative immunofluorescence images of de-cellularized matrix from Fb Act (clone 2) and Fb EV stained for fibronectin or collagen I.
F Relative colony area of SCC13 cells plated on either de-cellularized matrix from Fb Act (clone 2) or Fb EV. N = 3.
G Migration of SCC13 cells plated on either de-cellularized matrix from Fb Act (clone 2) or Fb EV. N = 6. The experimental setup is shown schematically above the
graph.
H Fb Act (clone 2) or Fb EV cells were cultured together in 2D with SCC13 cells. After 7 days of culture, SCC13 cells were identified by K14 staining and the number of
K14-positive colonies was quantified. N = 6.
I Quantification of SCC13 tumor spheroid area in single hanging drop including CM from Fb EV or Fb Act (clone 2) (including 1% FBS), DMEM/1% FBS, or DMEM/1%
FBS plus 20 ng/ml recombinant activin A. The area of the spheroid formed in one Fb EV sample was set to 1. N = 9–10 hanging drops.
J Representative images and quantification of K14-stained areas from 3D cultures of SCC13 cells seeded on top of either Fb Act (clone 2) or Fb EV. N = 3 independent
cultures, n = 3 histological sections.
K Representative pictures of tumors formed in NOD/SCID mice 6–7 weeks after intradermal injection of SCC13 cells with Fb Act (clone 2) or Fb EV. Tumor volume at
different time points of tumor development (6–7 weeks after injection). N = 5 tumors per group.
Data information: Bar graphs show mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 [one-way ANOVA with Bonferroni post-test (A, I), two-way ANOVA
with Bonferroni post hoc test (K), multiple Student’s t-test (G), unpaired Student’s t-test (C, D, F, H)]. Scale bars, 500 lm (E), 50 lm (H), or 100 lm (J). Exact P-values are
provided in Dataset EV3.
Source data are available online for this figure.
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marker LYVE1 in tumor sections, demonstrating that blood vessel
endothelial cells in these tumors are also mDia2-positive (Fig 4H).
mDia2 is overexpressed in human cancer stroma and negatively
correlates with survival
To determine the translational relevance of our findings, we
analyzed mDia2/DIAPH3 expression in human skin cancers and
found a significant increase in mDia2/DIAPH3 mRNA levels in
human BCC and cSCC samples as compared with normal skin
(Fig 5A). Cancer cells in these tumors express high levels of activin
A (Antsiferova et al, 2011), and mDia2/DIAPH3-positive cells were
particularly abundant in the stroma (Fig 5B).
Importantly, mDia2/DIAPH3 overexpression also occurs in
numerous other human cancers as revealed by analysis of datasets
from The Cancer Genome Atlas (TCGA) (Fig 5C). Furthermore, GEO
dataset analysis revealed that mDia2/DIAPH3 and INHBA were both
overexpressed in the stromal compartment of several cancers in
comparison with the respective normal tissue and also in breast
CAFs compared to normal breast fibroblasts (Fig 5D–G). Since most
patients with cSCCs do not die from their tumors, we could not
relate the INHBA/mDia2 expression levels to patient survival.
However, Kaplan–Meier survival analysis showed a strong associa-
tion of high co-expression of mDia2/DIAPH3 and INHBA with
decreased survival of patients with liver, stomach, and breast cancer
(Fig 5H).
mDia2 induces a pro-tumorigenic phenotype in skin fibroblasts
To determine the role of mDia2 in skin tumorigenesis, we performed
shRNA-mediated knock-down in mouse fibroblasts (Fig 6A). mDia2
silencing caused cell enlargement as previously seen for HeLa cells
(Beli et al, 2008) and reduced cell proliferation and migration, even
in the presence of exogenous activin A (Fig 6B and C). These results
were verified with a second shRNA and with primary human fibrob-
lasts (Fig EV4A–E). There was no compensatory upregulation of
mDia1 or mDia3, whereas expression of the genes encoding formin-
1 and formin-2 (Fmn1 and Fmn2) was increased (Fig 6D). Interest-
ingly, mDia2 knock-down strongly suppressed the expression of
several CAF genes (Fig 6D), particularly those that were upregulated
in the presence of activin A (Fig 2H). Vice versa, overexpression of
murine mDia2, which has ~85% homology to human DIAPH3 and
is active in human cells (Isogai et al, 2015a, 2016), in normal
human fibroblasts induced the expression of CAF markers, includ-
ing INHBA and DIAPH3 (Fig EV4F). In addition, the matrisome and
the secretome of fibroblasts overexpressing mDia2 promoted SCC13
colony formation (Fig EV4G and H).
mDia2 physically interacts with p53 and promotes CAF
marker expression
Previous studies had identified mDia2 in a complex with p53 (Isogai
et al, 2015a), which plays a non-autonomous tumor-suppressive
role in fibroblasts and suppresses CAF gene expression (Addadi
et al, 2010; Procopio et al, 2015). While mRNA levels of p53 and
those of the Notch effector CSL/RBP-J, which synergizes with p53 in
CAF activation (Procopio et al, 2015), were not altered upon mDia2
silencing, p53 accumulated in the nucleus of mDia2 knock-down
fibroblasts (Figs 6E and F, and EV4I–K). Activin A treatment of
fibroblasts had the opposite effect and reduced nuclear p53 levels
(Fig 6G). The effect of mDia2 on p53 is most likely the consequence
of a physical interaction of the endogenous proteins as revealed by
co-immunoprecipitation analysis of lysates from primary human
fibroblasts. Importantly, activin A treatment of these cells increased
the levels of p53 in the mDia2 immunoprecipitate (Fig EV4L). To
determine whether p53 nuclear accumulation in mDia2 knock-down
cells and repression of CAF markers are functionally linked, we
treated these fibroblasts with pifithrin-a (PFT-a), which destabilizes
nuclear p53, thereby diminishing p53-dependent transcriptional
control (Komarov et al, 1999). Indeed, PFT-a reduced the levels of
nuclear p53 in mDia2-depleted fibroblasts, and partially or comple-
tely rescued the mDia2-mediated downregulation of Postn and
◀
Figure 4. mDia2 is a direct activin A target gene in fibroblasts.
A Gene set enrichment analysis comparing the transcriptomes of fibroblasts isolated from pre-tumorigenic ear skin of female HPV8/Act-transgenic mice versus HPV8/
wt-transgenic mice (12–14 weeks old) to published datasets of cancer stroma or CAFs from different types of human cancers and from total actinic keratosis (AK)
samples. Positive or negative normalized enrichment scores (NES) correspond to enrichment of a given set in genes that are up- or downregulated, respectively, in
response to activin A. Data are presented as pseudo-heatmap with NES magnitude color-coded as indicated in the legend; all non-gray comparisons have
FDR < 0.10.
B Ingenuity pathway analysis of differentially regulated genes in FACS-isolated fibroblasts from activin A-transgenic mice in either a HPV8-negative or HPV8-positive
background compared to respective controls, showing selected top activated functions.
C (Top) Functional enrichment of the most upregulated genes using the Reactome database showing three unique significantly enriched terms. (Bottom) Filtered list of
upregulated genes based on the Matrisome database showing selected top upregulated collagens, ECM regulators, and secreted factors.
D mDia2 (Diap3) expression quantified by RNA sequencing of fibroblasts isolated from ear skin. N = 3 pools of 3–6 mice.
E Primary mouse fibroblasts were treated with activin A or TGF-b1 or vehicle for 6 h and analyzed by qRT–PCR (N = 3) and Western blot for mDia2 (Diap3) and mDia2
expression, respectively. The GAPDH loading control is identical to the one in Fig 2C, since the same membrane was probed for mDia2, aSMA, and GAPDH.
F Alignment of the sequences in the first intron of mDia2 (Diap3) genes of different species that harbor a SMAD2/3 binding element (SBE) (consensus sequence
highlighted in red and italics) (top). Chromatin immunoprecipitation of lysates from activin A- or TGF-b1-treated fibroblasts using a SMAD2/3 antibody and
amplification of the bound DNA with mDia2 primers (bottom). Pre-immune serum (IgG) was used as negative control, and the input chromatin is shown. N = 3.
G Immortalized mouse fibroblasts were transduced with a lentivirus expressing a DOX-inducible dominant-negative ActRIB mutant (dnActRIB) or an empty lentivirus
(EV), treated with activin A for 2.5 h, and analyzed by Western blot for mDia2 and GAPDH.
H Representative sections of ear skin tumors formed by SCC13 EV or SCC13 Act cells (clone 2) stained for mDia2 or K14 (green) (top), mDia2 (green) or MECA32/LYVE1
(red, bottom), and counterstained with Hoechst (blue).
Data information: Bar graphs show mean  SEM. ns P > 0.05, *P < 0.05, **P < 0.01 (one-way ANOVA with Bonferroni post hoc test). Scale bars: 100 lm. Exact P-values
are provided in Dataset EV3.
Source data are available online for this figure.
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Mmp13, which are negatively regulated by p53 (Sun et al, 2000;
Procopio et al, 2015), and also of other CAF marker genes (Fig 6H–
J). In line with these findings, Ingenuity pathway upstream regula-
tor analysis showed a negative correlation between expression of
INHBA and p53 target genes in FACS-isolated fibroblasts from Act
versus wt mice (Appendix Fig S2A). Overall, these results suggest
that activin A induces a CAF phenotype at least in part via mDia2
upregulation and consequent inhibition of p53 nuclear accumula-
tion. Consistent with this assumption, mDia2 knock-down in mouse
or human fibroblasts significantly reduced the colony-forming abil-
ity of SCC13 Act cells (Figs 6K and EV4M). Most importantly, the
efficient tumor formation by SCC13 Act cells that occurred in the
presence of control fibroblasts was almost completely abrogated in
the presence of mDia2 knock-down fibroblasts (Fig 6L). This corre-
lated with downregulation of periostin and nuclear accumulation of
p53 in the tumor stroma (Fig 6M and N). Furthermore, knock-down
of mDia2 in INHBA-overexpressing fibroblasts to levels seen in
control fibroblasts strongly reduced the positive effect of their secre-
tome and matrisome on SCC13 colony formation (Fig EV4N–P).
Taken together, mDia2 is crucial for the activin A-induced conver-
sion of fibroblasts into pro-tumorigenic CAFs and sufficient for
induction of a CAF phenotype in normal fibroblasts.
Repression of the activin A-mDia2 axis inhibits
squamous carcinogenesis
Finally, we tested whether blockade of signaling by endogenous
activin A inhibits squamous tumorigenesis. To this end, we
combined mouse preclinical SCC models with genetic and pharma-
cological manipulation of the endogenous activin A-mDia2 axis
in vivo and ex vivo.
First, we blocked activin A-induced signaling in fibroblasts
through dnActRIB (Appendix Fig S3A and B). Co-injection of SCC13
cells with dnActRIB-expressing fibroblasts delayed tumor growth
compared with SCC13 cells co-injected with control fibroblasts, and
mDia2-positive cells were significantly less abundant in the stroma
(Fig 7A and B). Many of the mDia2-positive cells in the stroma were
indeed fibroblasts as revealed by co-staining for mDia2 and the
pan-fibroblast marker PDGFR-a (Fig 7B). Important to note, co-
injection of SCC13 cells with normal fibroblasts resulted in a higher
rate of tumor formation as compared with injection of SCC13 cells
alone (compare Figs 1C and 7A).
Next, we generated SCC13 cells expressing the activin antagonist
follistatin (FST-315; Appendix Fig S3C). In the absence of fibro-
blasts, SCC13 EV cells formed tumors only several weeks after injec-
tion. Therefore, we only analyzed the tumors at the day of sacrifice
to avoid repeated anesthesia of the mice, which is required for
measurement of tumor volume. Importantly, FST overexpression
significantly suppressed tumor growth (Fig 7C) and also reduced
the expression of mDia2 in the stroma (Fig 7D).
A strong tumor-suppressive effect of activin A-mDia2 inhibition
was also seen when tumors formed by SCC13 Act cells were treated
ex vivo with recombinant human FST and/or SMIFH2, an mDia2
inhibitor (Isogai et al, 2015b). Vice versa, recombinant activin A
further promoted cell proliferation in tumor explants (Fig 7E). In
tumor spheroid models where SCC13 Act cells with fluorescence
labeled membranes were cultured with primary human fibroblasts,
FST or SMIFH2 suppressed spheroid expansion (Fig 7F).
Finally, the therapeutic potential of activin A inhibition was
shown in vivo, since injection of FST into A431 ear xenograft tumors
strongly reduced their growth. This correlated with downregulation
of mDia2 expression in the stroma (Fig 7G). Together, these find-
ings reveal a crucial role of the activin A-mDia2 signaling pathway
in squamous carcinogenesis by reprogramming of normal fibrob-
lasts into CAFs. Therefore, inhibition of this axis is a promising
strategy for the treatment of squamous cancers and other activin A-
dependent malignancies (Fig 7H).
Discussion
Here, we show that activin A captures major players in normal cell
biology to reprogram fibroblasts into pro-tumorigenic CAFs. There-
fore, blocking of this signaling axis offers exciting opportunities for
cancer prevention and treatment. Importantly, the activin signaling
pathway discovered in this study was not activated by TGF-b1,
◀
Figure 5. mDia2 (DIAPH3) is overexpressed in human cancers and negatively correlates with survival.
A qRT–PCR for mDia2/DIAPH3 relative to RPL27 using RNA from normal human skin (N = 11), SCCs (N = 9), and BCCs (N = 7).
B Representative skin/tumor sections from normal human skin, cSCC, and BCC patients stained for mDia2/DIAPH3. Note the strong mDia2/DIAPH3 positivity in the
tumor stroma. Scale bars: 100 lm. D: dermis, E: epidermis: T: tumor.
C Expression levels of mDia2/DIAPH3 in tumor and normal tissues based on TCGA cancer data (TCGA data version 20141017, http://firebrowse.org/). Gene expression
levels were presented as normalized log2 RSEM (RNA-Seq by Expectation–Maximization) index from the database. BLCA: bladder urothelial carcinoma (N = 408
and 19 tumor and normal tissue samples, respectively); BRCA: breast invasive carcinoma (N = 1,100 and 112); CESC: cervical SCC (N = 306 and 3); ESCA:
esophageal SCC (N = 185 and 11); HNSC: head-neck SCC (N = 522 and 44); LIHC: liver hepatocellular carcinoma (N = 373 and 47); LUSC: lung SCC (N = 501 and
51); PAAD: pancreatic adenocarcinoma (N = 179 and 4); PRAD: prostate adenocarcinoma (N = 496 and 50); READ: rectum adenocarcinoma (N = 167 and 10); STES:
stomach and esophageal carcinoma (N = 600 and 46); UCEC: uterine corpus endometrial carcinoma (N = 546 and 35). Box plot shows relative mDia2/DIAPH3
expression in human tumor (red) and normal (blue) tissue. Boxes indicate the interquartile range, whiskers indicate data points within 1.5 times interquartile
range, dots outside the whiskers indicate outliers, and the central line indicates median.
D–G Relative gene expression of mDia2/DIAPH3 and INHBA in the stroma of intrahepatic cholangiocarcinoma, breast and colorectal cancers versus stroma of respective
normal tissues based on datasets GSE45001 (D) (N = 10 normal tissue & 10 cancer samples), GSE9014 (E) (N = 4 and 13), and GSE35602 (F) (N = 6 and 53), and in
CAFs from breast cancer samples versus normal breast fibroblasts (GSE29270 dataset) (G) (N = 5 and 23). NS: normal stroma; CS: cancer stroma; NF: normal
fibroblasts; CAF: cancer-associated fibroblasts. The expression values of the datasets were obtained using GEO2R tool in the GEO database.
H Kaplan–Meier survival curves based on datasets from GEO, EGA, and TCGA, demonstrating that high expression of both mDia2/DIAPH3 and INHBA in patients with
liver, stomach, and breast cancer correlates with poor overall survival. Data and statistical analyses were collected from KMPlotter.
Data information: Graphs show mean  SEM. P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired Student’s t-test (D–G) and one-way ANOVA with
Bonferroni post hoc test (A). Exact P-values are provided in Dataset EV3.
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another key player in CAF formation (Calon et al, 2014). Rather,
TGF-b1 promotes myofibroblast differentiation, strongly suggesting
that activin A and TGF-b1 induce distinct types of CAFs.
A few additional drivers of the CAF phenotype have been
described, e.g., loss of Notch/CSL signaling, in particular when
combined with p53 downregulation (Procopio et al, 2015). Further-
more, DNA damage or adrenergic signaling in tumor cells induced
CAF activation in mammary and ovarian cancer models, which was
at least in part mediated by Inhba expression in the tumor cells
(Fordyce et al, 2012; Nagaraja et al, 2017). These results indicate
important connections between different CAF inducers.
Through transcriptional activation of mDia2, activin directly
promotes the migratory capacity of fibroblasts and also induces the
expression of CAF markers, which include various cytokines and ECM
components. These activities are likely to be beneficial during wound
healing, when activin A is transiently upregulated and promotes the
healing process (Munz et al, 1999). However, upon long-term activa-
tion and in the presence of mutated cancer cells, the secretome and
the matrisome of activin A-exposed fibroblasts promoted malignant
features of SCC cells in an mDia2-dependent manner. This is consis-
tent with the finding that high mDia2 expression supported ECM
remodeling and invasion of mammary CAFs in culture (Calvo et al,
2013). Remarkably, overexpression of mDia2 alone induced CAF
properties in normal fibroblasts. Thus, mDia2 is required for various
pro-tumorigenic activities of activin A and sufficient for establishment
of a CAF phenotype. The in vivo relevance of these findings was
demonstrated in xenograft models, where co-injection of mDia2
knock-down fibroblasts with SCC cells overexpressing activin A
strongly diminished the potent effect of activin A on tumor growth
and progression. The strong correlation between increased activin A-
mDia2 expression and reduced survival of patients with different
malignancies supports the clinical relevance of our findings.
The observations that mDia2 binds p53 and that silencing of mDia2
in fibroblasts resulted in p53 accumulation in the nucleus and
concomitant lower expression of CAF markers shed light on the mech-
anism whereby activin A regulates the CAF phenotype. p53 exerts a
non-autonomous tumor-suppressive role in fibroblasts through
suppression of paracrine-acting factors that promote tumor formation
(Moskovits et al, 2006; Addadi et al, 2010). Accordingly, p53 down-
regulation in fibroblasts promoted prostate and skin tumor growth
(Addadi et al, 2010; Procopio et al, 2015). Interestingly, lung cancer
cells were shown to secrete unknown factors that suppress p53 activ-
ity in fibroblasts. Our results suggest that activin A may be one of
these factors, since it reduced the levels of p53 in the nucleus. They
further show that induction of pro-tumorigenic, p53-repressed CAF
genes in fibroblasts by activin A is dependent on mDia2 and that
mDia2 overexpression is sufficient to promote expression of these
genes. The functional relevance of this interaction for the in vivo situa-
tion is supported by the negative correlation of activin A overexpres-
sion in mouse skin with the expression of p53 target genes.
In recent years, non-invasive treatments of NMSC became avail-
able, including topical application of the TLR7 agonist imiquimod,
and systemic use of immune check point inhibitors, which rely on
immune cell-mediated apoptosis of cancer cells (Love et al, 2009;
Migden et al, 2018), or of hedgehog signaling inhibitors for BCC,
which directly target the tumor cells (Gutzmer & Solomon, 2019).
Our data suggest targeting of the fibroblast-cancer cell cross-talk as
a promising alternative. This would offer clinical advantages, since
fibroblasts are genetically more stable and less resistant to therapeu-
tic intervention compared with tumor cells (Pure & Lo, 2016). Both
follistatin and SMIFH2 efficiently blocked the pro-tumorigenic effect
of activin A through inhibition of the activin A-mDia2 axis. Consis-
tent with these findings, follistatin suppressed metastasis in mouse
breast and lung cancer models (Ogino et al, 2008; Seachrist et al,
2017) and improved the efficacy of platinum chemotherapy in the
management of activin A-induced lung adenocarcinoma (Marini
et al, 2018). However, a role of fibroblasts in the therapeutic effect
of activin A inhibition has as yet not been reported and relevant
◀
Figure 6. Knock-down of mDia2 in fibroblasts suppresses squamous cell malignancy and tumor growth via p53.
A Immortalized mouse fibroblasts were transduced with a lentiviral vector expressing different mDia2-targeting shRNAs (shmDia2 #1-3) or empty vector (sh-EV).
The knock-down was confirmed by qRT–PCR (N = 3), Western blot, and immunofluorescence.
B, C Ki67 staining (B) and migration in scratch assays (C) of mDia2 knock-down and control mouse fibroblasts. N = 3.
D qRT–PCR for mDia1, mDia3, Fmn1, and Fmn2 and several CAF genes relative to Rps29 using RNA from control (sh-EV) and mDia2 knock-down (sh-mDia2)
fibroblasts. N = 3.
E Representative images of mDia2 knock-down and control mouse fibroblasts stained for p53 (left), and quantification of cells showing accumulation of p53 in the
nucleus (right). N = 3.
F, G Representative Western blots for p53, vinculin, and histone H1 using nuclear and cytoplasmic fractions and total lysate of mDia2 knock-down (F) or activin
A-treated fibroblasts (6 h, 20 ng/ml) (G) and control mouse fibroblasts and quantification of the nuclear p53/histone H1 ratio. Vinculin and histone H1 were used
as loading controls for the cytoplasmic and nuclear fractions, respectively. N = 6.
H Representative Western blots for p53, mDia2, and GAPDH using total lysates of mDia2 knock-down and control mouse fibroblasts treated for 24 h with pifithrin-a
(PFT-a) (15 lM).
I Representative p53 immunofluorescence images of mDia2 knock-down mouse fibroblasts treated with PFT-a or vehicle (DMSO) (top) and quantification of cells
showing accumulation of p53 in the nucleus (bottom). N = 3.
J qRT–PCR for mDia2, Postn, Mmp13, Fn1, Spp1, and Acta2 relative to Rps29 using RNA from mDia2 knock-down and control fibroblasts treated with PFT-a or
vehicle. N = 3.
K Colony size of SCC13 Act cells (clone 2) after co-culture with either immortalized mDia2 knock-down (sh-mDia2) or control (sh-EV) mouse fibroblasts. N = 4.
L Representative pictures of 5-week-old tumors formed upon intradermal co-injection of SCC13 Act cells (clone 2) with sh-EV or sh-mDia2 knock-down immortalized
mouse fibroblasts. Graph shows tumor volume at different time points of tumor development. N = 3–5 tumors per group.
M, N Representative immunofluorescence images of sections from ear skin tumors formed by SCC13 Act (clone 2) co-injected with sh-EV or sh-mDia2 fibroblasts,
stained for E-cadherin (green) and periostin or p53 (red), and counterstained with Hoechst (blue).
Data information: Bar graphs show mean  SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, unpaired Student’s t-test (B, E–G, I, and K) and one-way ANOVA
with Bonferroni post hoc test (A, C), two-way ANOVA with Bonferroni post-test (D, J, L). Scale bars: 100 lm. Exact P-values are provided in Dataset EV3.
Source data are available online for this figure.
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target genes remain to be identified. Blocking of mDia2 in fibro-
blasts may well have a similar effect, but prolonged exposure to
SMIFH2 leads to p53 downregulation (Isogai et al, 2015b), and
reports showing that downregulation of mDia2 in certain cancer
cells promotes their motility have to be considered and may limit
the usefulness of mDia2 inhibitors (Di Vizio et al, 2009; Creekmore
et al, 2011; Pettee et al, 2014). Therefore, inhibition of activin A or
its receptors is the more promising approach. In some cancers, such
as melanoma, inhibition of activin A additionally promotes anti-
tumor immunity, e.g., via its action on natural killer cells (Donovan
et al, 2017; Rautela et al, 2019). Interestingly, soluble activin type II
receptors are in clinical trials for the treatment of activin A-induced
cancer cachexia or bone destruction, and revealed low toxicity
(Pearsall et al, 2008; Zhou et al, 2010). These and our results raise
the exciting possibility of developing novel targeted therapies that




NOD/SCID (NOD.CB17-Prkdcscid/NCrCrl) mice, PDGFRa-eGFP
transgenic mice (Hamilton et al, 2003), and transgenic mice overex-
pressing INHBA in keratinocytes (Act mice) (Munz et al, 1999) with
or without the HPV8 oncogenes (Schaper et al, 2005; Antsiferova
et al, 2017) were used. They were housed under specific pathogen-
free conditions and received food and water ad libitum. Mouse
maintenance and all animal experiments had been approved by the
veterinary authorities of Zurich, Switzerland.
Primary cells and cell lines
SCC13 cells (human cutaneous squamous cell carcinoma cell line;
Rheinwald & Beckett, 1981) were kindly provided by Dr. Petra
Boukamp, Leibniz Institute for Environmental Research, Düsseldorf,
Germany, and verified to be pure SCC13 cells by the Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DMSZ) GmbH,
Braunschweig, Germany.
A431 cells (epidermoid vulvar carcinoma cells, Giard et al, 1973)
were purchased from Sigma, Munich, Germany.
Primary foreskin fibroblasts were established from human fore-
skin and kindly provided by Dr. Hans-Dietmar Beer, University of
Zurich, Switzerland.
All mouse primary cells and immortalized fibroblast lines were
established in our laboratory as previously described (Hiebert et al,
2018).
All cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS) and peni-
cillin/streptomycin.
3D organotypic skin cultures
Scaffold-free organotypic 3D cultures were established according to
Berning et al (2015). For this purpose, 1.86 × 106 human fibroblasts
were seeded onto 6-well inserts with a 0.4 lm transparent polyethy-
lene terephthalate (PET) membrane in 1.5 ml of sterile-filtered
Medium A (DMEM with high glucose/L-glutamine and DMEM/F-12
GlutaMAXTM in a 1:1 ratio), supplemented with 0.2 mg/ml 2-
phospho-L-ascorbic acid, 1 ng/ml TGF-b1, 2.5 ng/ml epidermal
growth factor (Sigma-Aldrich), 5 ng/ml fibroblast growth factor 2
(PeproTech), and 5 lg/ml insulin (Sigma-Aldrich). Outside of the
insert, another 12 ml of Medium A was added to Falcon 6-well
Deep Well tissue culture-treated polystyrene plates (Corning). Seed-
ing of fibroblasts was repeated after 2 and 4 days. Medium A inside
and outside the 6-well insert was replaced every second day until
day 31. On day 32, 0.928 × 106 SCC13 or A431 cells were seeded on
top of the dermal layer with 1.5 ml sterile-filtered Medium B
[DMEM with high glucose/L-glutamine and DMEM-F12 GlutaMAXTM
in a 1:1 ratio, supplemented with 0.2 mg/ml 2-phospho-L-ascorbic
acid, 0.0084 lg/ml cholera toxin, 0.4 lg/ml hydrocortisone, with
our without 1 lg/ml doxycycline (all from Sigma-Aldrich)] accord-
ing to the experimental setup. In addition, another 12 ml of Medium
B was added to the well. After 3 days, the medium was removed
from the insert, and the outside medium was replaced by 12 ml of
◀
Figure 7. Inhibition of activin A-mDia2 signaling suppresses squamous tumor growth.
A Tumor volume at different time points after co-injection of SCC13 cells with EV or dnActRIB fibroblasts. N = 5 tumors.
B Representative immunofluorescence images of sections from ear skin tumors formed by SCC13 cells co-injected with EV or dnActRIB fibroblasts, stained for K14 (left)
or PDGFRa (right) (green) and mDia2 (red), and counterstained with Hoechst (blue). Bar graph shows the percentage of mDia2-positive area. N = 3.
C SCC13 EV or SCC13 Fst cells were injected into the ear skin of NOD/SCID mice, and tumor weight was determined 12 weeks after injection. N = 9–10 tumors.
D Representative immunofluorescence images of sections from ear skin tumors formed by SCC13 EV or SSC13 Fst cells, stained for K14 or mDia2 (red), and
counterstained with Hoechst (blue). Bar graph shows the percentage of mDia2-positive area. N = 3.
E Tumors formed by SCC13 Act cells were treated ex vivo for 6 h with follistatin (FST) (50 ng/ml) and/or SMIFH2 (10 lM), or with activin A (20 ng/ml) and stained for
Ki67. N = 3 tumor explants, n = 4 histological sections.
F Representative images of spheroids formed by SCC13 Act cells labeled with PKH67 (green) with primary human fibroblasts embedded in collagen gels and graph
showing increase in the spheroid area between day 0 and day 3. Spheroids were treated with either FST (50 ng/ml) or SMIFH2 (10 lM) or left untreated. N = 6–8
tumor spheroids.
G Increase in A431 tumor volume (mm3) compared to day 0 (time when the tumors were first injected with FST, approximately 3–4 weeks after injection of the cells)
upon treatment of the tumors with FST (100 ng per injection) or vehicle (PBS). N = 3–5 tumors per group. Representative immunofluorescence images of the FST or
vehicle-treated tumors, stained for mDia2 (green) and K14 (red), counterstained with Hoechst (blue).
H Proposed role of activin A secreted by cancer cells in inducing a pro-tumorigenic CAF phenotype in fibroblasts. Activin A signaling (blocked by follistatin or dnActRIB
(not shown in the figure) induces upregulation of mDia2 (inhibited by SMIFH2), which in turn contributes to tumor development by reducing the nuclear p53 pool
and promoting the expression of CAF marker genes, fibroblast proliferation, and migration.
Data information: Bar graphs show mean  SEM. ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (unpaired Student’s t-test (B-D), one-way ANOVA with
Bonferroni post-test (E, F), two-way ANOVA with Bonferroni post-test (A, G)). Scale bars: 100 lm. Exact P-values are provided in Dataset EV3.
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fresh medium B. Cultures on the inserts were then cultured at the
air–liquid interface. The outside medium was replaced every second
day by 12 ml of Medium B until collection (day 60). Mature cultures
were harvested, bisected, and embedded in tissue freezing medium
(Leica Microsystems) for further analysis by histochemical or
immunofluorescence staining.
Cell proliferation assay
Cell proliferation was determined by counting of cells or by analysis
of BrdU incorporation (Hiebert et al, 2018).
Cloning of cDNAs into the pInducer20 plasmid
The coding sequences for INHBA, FST, or dnActRIB were amplified
from plasmids using the primers listed in Appendix Table S1, cloned
into the pENTR/D-TOPO vector (K240020, Thermo Fisher Scien-
tific), and subsequently into the pInducer20 vector (kindly provided
by Dr. S. Elledge) using the LR Clonase II Enzyme mix (#11791019,
Thermo Fisher Scientific).
Lentiviral production
HEK293T cells at 30% confluency were transfected overnight in
DMEM/10% FBS without P/S using jetPEI Transfection Reagent (#101-
40N, Polyplus-Transfection SA). For each 10 cm dish, 5 lg DNA was
incubated with 1.75 lg pMD2.G and 3.25 lg pCMV-dR8.91 (#12259
Addgene). On the next day, the medium was replaced by DMEM/10%
FBS/P/S. Cells were cultured for at least 48 h to allow production of
the virus. The supernatant was filtered through a Filtropur S 0.2-lm fil-
ter (#83.1826.001, Sarstedt) and stored at 80°C.
Lentiviral transduction and generation of stably transfected
cell cultures
Fibroblasts, SCC13, or A431 cells were grown to 60–70% confluency
in 6 cm dishes and incubated with 1 ml/dish of viral supernatant in
DMEM/10%FBS/P/S supplemented with 8 lg/ml of polybrene for
6 h at 37°C/5% CO2. Afterward, fresh medium with polybrene was
added. Two days later, the selection process was started by addition
of 1 lg/ml G418/geneticin (#11811031, Thermo Fisher Scientific)
for pInducer20-transduced cells or 0.5 lg/ml puromycin (P8833,
Sigma-Aldrich) for pLKO.1-transduced cells.
Lentivirus-mediated expression of mDia2 shRNAs
Immortalized mouse dermal fibroblasts were infected with lentiviral
shRNA vectors designed by The RNAi Consortium (TRC). Three
shRNAs directed against mouse mDia2 in the pLKO.1 lentiviral
vector were tested (Appendix Table S2). Primary human dermal
fibroblasts were infected with lentiviruses pLKO.1-shmDia2 #1;
TRCN0000150903, which target both mDia2 and DIAPH3 (Isogai
et al, 2015a,b).
Transient transfection of fibroblasts
Wild-type Flag-tagged mDia2 cDNA (Isogai et al, 2015a, 2016) was
subcloned into the retroviral pMX vector (Cell Biolabs). One
microgram pMX Flag-mDia2 or empty vector and LipofectamineTM
2000 (#11668030, Invitrogen) were incubated with Opti-MEMTM I
Reduced Serum Medium (#31985062, Thermo Fisher Scientific) at
room temperature for 20 min. The mixture was then added to
primary human fibroblasts. After 6-h incubation, medium was
replaced by normal culture medium containing 10% FBS. Cells were
allowed to recover for 48 h prior to analysis.
Collagen gel contraction assay
Gel contraction was performed in 24-well plates coated with 1%
BSA at 37°C for 1 h. For each gel, 120 ll HEPES, 26 ll 10× DMEM,
16 ll Milli-Q water, and 240 ll of cell suspension (420,000 cells/ml)
were mixed. 198 ll of TeloCol Type I Bovine Collagen Solution
(#5026, Advanced BioMatrix) was added to the well. The plate was
incubated at 37°C and 5% CO2 for 90 min to solidify. Afterward,
500 ll of DMEM with 1% FBS and 1% P/S were added to the gels.
Gels were incubated with activin A (20 ng/ml) and/or TGF-b1
(1 ng/ml; #100-21, PeproTech) at 37°C/5% CO2, and contraction
was monitored for 12–72 h.
Culture of SCC13 cells with fibroblasts
Equal numbers of SCC13 cells and fibroblasts were seeded together
on glass slides in 24-well plates. The cells were co-cultured in
complete DMEM with DOX (1 lg/ml) for 7 days and subsequently
stained with K14 antibody to measure the SCC13 colony number/
area.
Spheroid formation and growth assay
Twenty microlitre growth medium containing 2,000 SCC13 Act
cells, which had been pre-treated with PKH67 (Sigma-Aldrich)
for cell membrane labeling, was placed on the lids of 6-cm
culture plates. To prevent dehydration, 5 ml PBS was added to
the bottom. Cells were incubated at 37°C and 5% CO2 for
72 h. Upon aggregate formation in the drops, spheroids were
collected and transferred onto a collagen gel pre-seeded with
primary human fibroblasts. They were incubated for 3 addi-
tional days in complete DMEM with DOX. Fluorescence images
were captured on a ZOETM Fluorescent Cell Imager (Bio-Rad),
and spheroid outgrowth was quantified using ImageJ software.
To analyze anchorage-independent growth, spheroids were incu-
bated in different culture media and analyzed for increase in
spheroid area.
RNA isolation and qRT–PCR
RNA isolation and quantitative qRT–PCR were performed as described
(Hiebert et al, 2018) using primers listed in Appendix Table S3.
Values obtained for the first control were set to 1.
Preparation of protein samples and Western blot analysis
Preparation of protein lysates and Western blot were performed
using standard procedures. Proteins from conditioned medium were
precipitated by addition of trichloroacetic (10% v/v), pelleted by
centrifugation at 20,000 g for 15 min at 4°C, washed twice with
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ice-cold acetone, air-dried, and resuspended in 25 ll 2× Laemmli
buffer.
Antibodies against INHBA (sc166503, Santa Cruz, 1:500 diluted),
mDia2 (recognizing both mDia2 and DIAPH3; 1:5,000 diluted) (Iso-
gai et al, 2015a,b), aSMA (A2547, Sigma-Aldrich, 1:500 diluted),
p53 (sc-126, Santa Cruz or AB17990, Abcam, 1:500 diluted), MYC-
tag (AB9106, Abcam, 1:1,000 diluted), a-tubulin (T5168, Sigma-
Aldrich. 1:10,000 diluted), vinculin (V4505, Sigma-Aldrich, 1:2,000
diluted), histone H1 (AB134914, Abcam, 1:500 diluted), and GAPDH
(#5G4, HyTest, 1:10,000 diluted) were used. Secondary antibody
was anti-rabbit or anti-mouse IgG (W4011 and W4021, Promega,
1:8,000 diluted) conjugated with horseradish peroxidase, and
chemiluminescence was determined using the WesternBright ECL
Detection System (Advansta). Bands were visualized using Fusion
Solo 6S (Witeg AG), and intensity was quantified with ImageJ soft-
ware (National Institutes of Health).
Immunoprecipitation
Protein lysates from 1 × 107 primary human foreskin fibroblasts
were prepared using 0.5 ml cell lysis buffer (0.1% NP40 in PBS with
1× protease inhibitor cocktail (Roche)) and collected by centrifuga-
tion at 14,000× g for 15 min at 4°C. 200 ll of protein lysate was
incubated with 1–2 lg of normal rabbit IgG (#2729, Cell Signaling,
1:1,000 diluted) or DIAPH3 antibody (Isogai et al, 2015a,b; 1:1,000
diluted) under rotation overnight at 4°C. The immunocomplex was
then mixed with 20 ll solution containing DynabeadsTM Protein A
(#10002D, Thermo Fisher Scientific). Antibody-bound beads were
incubated for 20 min at room temperature on a rotator, recovered
using a magnetic separation rack, and washed five times with
0.5 ml lysis buffer. Immunoprecipitated proteins were eluted with
2× Laemmli sample buffer.
Gelatin zymography
Conditioned media were collected from the 3D organotypic skin
cultures, centrifuged, and concentrated using an Amicon Ultra-4
Centrifugal Filter Unit device with 3 kDa cut-off (UFC800308,
Merck) at 4,500 g for 30 min at 4°C. Supernatants were subjected to
electrophoresis in a 7.5% SDS–polyacrylamide gel co-polymerized
with gelatin (1 mg/ml, Sigma-Aldrich). Enzymatically active MMPs
were detected as transparent bands in the Coomassie Brilliant Blue-
stained gelatin gel.
Nucleus/cytosol fractionation
Cells were lysed with 350 ll 0.1% NP40-PBS with 1× protease inhi-
bitor cocktail (#11697498001, Roche) on ice, and lysates were
centrifuged at 17,000 g for 3 min. The supernatant included cyto-
plasmic extract. The nuclear pellets were washed with 800 ll lysis
buffer, centrifuged at 17,000 g for 3 min (3× each), and resuspended
in 70 ll of 2× Laemmli buffer.
Histology and immunostaining
Histological analysis and immunostainings were performed as
described (Hiebert et al, 2018) using the antibodies listed in
Appendix Table S4.
Migration assays
Chemotactic transwell migration was assessed as described (Antsif-
erova et al, 2017). Primary mouse fibroblasts were incubated for
24 h in DMEM/1% FBS for baseline measurements and in DMEM/
1% FBS supplemented with activin A (#338-AC, 1–20 ng/ml) (R&D
Systems) in the lower compartment of the chamber.
For transwell migration assays, SCC13 cells were seeded on the
insert and fibroblasts were seeded on the lower chamber.
Migration of cells toward the factors secreted by fibroblasts was
determined.
To determine the capacity of the matrix deposited by fibroblasts
to stimulate SCC cell migration, SCC13 cells were seeded on culture
inserts (#80209, Ibidi) that were placed on top of the matrix that
had been deposited by fibroblasts. The insert was then removed for
migration assays.
For scratch assays, cells were grown to 100% confluency and
treated with 2 lg/ml mitomycin C for 2 h. One or several scratches
were made into the cell layer using a sterile 200 ll pipette tip. Dead
cells and debris were washed off with pre-warmed PBS. The same
area was photographed directly after scratching and at different time
points thereafter.
FACS and RNA sequencing
Cell dissociation, FACS, RNA sequencing, and bioinformatics
analysis were performed as previously described (Antsiferova
et al, 2017). Briefly, fibroblasts from the ear skin of female mice
(13–15 weeks old, CD1 genetic background) were isolated based
on the fibroblast marker CD140a (antibody #135908, BioLe-
gend). RNA was isolated using the RNeasy Micro Kit (Qiagen),
analyzed via TapeStation (Agilent Technologies), and samples
with RIN > 7 were adjusted to 100 ng and subjected to RNA
sequencing via poly-A enrichment, True-Seq library preparation,
and sequencing on an Illumina HiSeq 2500 instrument (Illu-
mina). Quality control via FastQC showed rRNA mapping rates
of < 5% and over 30 million reads for all samples. RSEM-
normalized gene count data were analyzed for genes that are
regulated by activin A in the presence or absence of the HPV8
transgene (n = 3).
GEO2R and KMPlotter (Kaplan–Meier Plotter) analysis
Using the GEO2R analysis tool in the GEO database, mDia2/DIAPH3
and INHBA gene expression values were acquired from public
mRNA datasets of human cancers (Barrett et al, 2013).
Survival graphs were generated using the KMPlotter gene expres-
sion-based survival analysis web application by integrating gene
expression and clinical data simultaneously with statistical analysis
of log-rank P value (Nagy et al, 2018).
Preparation of fibroblast secretomes and matrisomes
Cells were plated at 70–90% confluency in DMEM/10% FBS/P/S. On
the following day, they were pre-treated with 2 lg/ml mitomycin C
and cultured in starvation medium (DMEM/1%FBS/P/S) with 1 lg/ml
DOX for an additional 3 days. Conditioned media and ECM were
prepared as described (Hiebert et al, 2018).
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Skin tumorigenesis assays
Tumorigenesis assays in mouse ear skin were performed as
described (Procopio et al, 2015). SCC13 or A431 cells overexpress-
ing INHBA or FST or control cells were treated with DOX for 24 h.
In brief, 3 ll cell suspension of 2 × 105 cells in Hank’s buffer was
injected intradermally into the ear of male NOD/SCID mice, 10–
15 weeks of age. For tumor cell/fibroblast co-injection experiments,
we injected 105 cancer cells and an equal number of fibroblasts.
Mice were injected with DOX (20 mg/kg) every other day. Tumor
formation was monitored over 5 weeks.
For follistatin treatment experiments, A431 cells were injected
intradermally and tumor formation was observed during 4 weeks.
Tumors were then treated with follistatin (100 ng) or vehicle (PBS)
every 3–4 days by direct injection into the tumor. Four days after
the last injection, tumors were harvested.
Human skin biopsies
Normal human skin and skin cancer samples were obtained anony-
mously from the Department of Dermatology, University Hospital of
Zurich (in the context of the Biobank project), approved by the local
and cantonal Research Ethics Committees. Normal skin was from
healthy adult volunteers or from the edges of skin tumors. BCC or
SCC was diagnosed by experienced pathologists. Informed consent
was obtained from all subjects and the experiments conformed to
the principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report.
Prediction of SMAD2/3-mediated transcriptional regulation of
mDia genes
The numbers of predicted SMAD2/3 binding sites 100 kb upstream
of the TSS or within the genomic region of the DIAPH1-3 genes were
determined using the GTRD ChIP-seq database (http://gtrd.biouml.
org/) (Yevshin et al, 2017).
Chromatin immunoprecipitation (ChIP)
Primary mouse dermal fibroblasts (approx. 5 × 108 cells) at 80–90%
confluence, which had been pre-treated with activin A (20 ng/ml)
or TGF-b1 (1 ng/ml) for 6 h, were collected, resuspended in DMEM,
and subjected to ChIP as previously described (Wilanowski et al,
2008). The purified DNA fragments were used for PCR amplification
using the primers listed in Appendix Table S5.
Ex vivo tumor explant cultures
Ear tumors were cut into fragments of approximately 0.5 cm2 and
cultured at the air–liquid interface in DMEM/10% FBS supple-
mented with 5 lg/ml insulin (I5500), 0.1 nM cholera toxin (C8052),
10 ng/ml epidermal growth factor (E4127), 50 IU/ml P/S, and
0.4 lg/ml hydrocortisone (#386698) (all from Sigma-Aldrich). After
overnight incubation, they were treated with activin A (20 ng/ml),
follistatin (50 ng/ml) (#120-13, PeproTech), SMIFH2 (10 lM)
(S4826, Sigma-Aldrich), or combinations for 6 h and embedded in
paraffin. Sections were analyzed by immunohistochemistry using a
Ki67 antibody (ab15580, Abcam, 1:500 dilution).
Ingenuity pathway analysis
Lists of genes differentially expressed in FACS-isolated fibroblasts
from activin-overexpressing versus control mice were uploaded
to Ingenuity Pathway Analysis (Qiagen). Core analysis was
performed with filtered lists of significantly up- and downregulated
genes with |Log2Ratio|>1 and FDR < 0.05 in three comparisons: Act/
wt versus wt/wt, Act/HPV versus wt/HPV, and Act/HPV versus wt/
wt. Data tables associated with “Diseases & Functions” and
“Upstream Regulators” were exported to identify highly activated
enriched functions and regulators in activin A-exposed fibroblasts.
Selected functions were arranged in a spreadsheet, and their activa-
tion z-scores were color-coded for visualization. Original IPA output
data with unfiltered “Diseases & Functions” and “Upstream Regula-
tors” for all comparisons are provided in Dataset EV1. Additional
enrichment of upregulated genes was done using Reactome and
matrisome databases (Naba et al, 2012).
Gene set enrichment analysis (GSEA)
Sets of significantly up- and downregulated genes were generated by
analyzing published microarray data of CAFs or total stroma of vari-
ous types of human cancer (see Dataset EV2). Original gene sets were
uploaded to GSEA and filtered to those mapped by gene symbol and
present in the tested datasets. The gene sets were tested against the
GSEA-generated ranked gene lists of the individual genotype compar-
isons Act/wt versus wt/wt, Act/HPV versus wt/HPV, Act/HPV versus
wt/wt, and the combined [all]/Act/[all] versus wt/[all] comparison.
Four separate GSEA runs were completed: (i) testing all individual
genotype comparisons against gene sets and (ii) testing the [all]/Act
versus [all]/wt comparison against gene sets. GSEA results were orga-
nized in tables, and the normalized enrichment scores (NES) and false
discovery rate (FDR) values were color-coded for visualization.
The paper explained
Problem
Skin cancer is by far the most common type of cancer worldwide.
Since stromal alterations strongly contribute to the high incidence of
skin cancer, treatments targeting the cancer microenvironment appear
very attractive. In this context, the role of cancer-associated fibro-
blasts (CAFs) is being increasingly recognized. However, the molecular
mechanisms of CAFs in skin tumorigenesis are still poorly character-
ized.
Results
We discover that activin A promotes skin tumorigenesis via repro-
gramming of fibroblasts into CAFs. This effect is mediated to a large
extent via activin A-induced upregulation of the formin mDia2. Activa-
tion of the activin A-mDia2 axis negatively correlates with survival in
different human cancers and blocking of this axis at multiple levels
inhibited skin carcinogenesis in mouse models.
Impact
Our study suggests inhibition of the activin A-mDia2 axis at multiple
levels as a therapeutic strategy in cancer patients. Since activin recep-
tor inhibitors are in clinical trials for the treatment of activin A-
induced cancer cachexia and muscle wasting, our findings raise the
exciting possibility that blocking of activin A may inhibit both cancer
growth and cancer-induced morbidity.
18 of 21 EMBO Molecular Medicine 12: e11466 | 2020 ª 2020 The Authors
EMBO Molecular Medicine Michael Cangkrama et al
Original and filtered gene sets, ranked gene lists, and original GSEA
output data for all experiments are provided in Dataset EV2.
Statistics
Statistical analysis was performed using the Prism software, version
7 for Mac OS X or Windows (GraphPad Software Inc). For compar-
ison of two groups, unpaired Student’s t-test was performed; for
comparison of more than two groups, one-way or two-way ANOVA
and Bonferroni’s multiple comparisons test were used. ns P > 0.05,
*P < 0.05, **P < 0.01, ***P < 0.001 ****P < 0.0001.
Data availability
The RNA-seq data have been deposited in NCBI’s Gene Expression
Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) (GSE130017).
Expanded View for this article is available online.
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